vTv Therapeutics Inc. announced that the first patient has been screened in the Company's CATT1 pivotal trial evaluating Cadisegliatin as an adjunct treatment of type 1 diabetes (T1D). CATT1 is designed to be a registrational study and is one of several trials that will form the core of the regulatory submission for cadisegliatin, a potential first-in-class, oral, liver selective, glucokinase activator for T1D that has been dosed in over 500 subjects to date, including 300 patients with T1D and type 2 diabetes (T2D). CATT1 is design to be a registrational study.

CATT1 is designed to been a registrational study and is One of several trials that will form The core of the regulatory submission for Cadisegliatin, a potentially first-in-class, Oral, liver selective, glucokinases activator for T1D That has been dosed in over500 subjects to date, including 300 patient with T1D and type2 diabetes (T2D).